What is the recommended management plan for infants with Beckwith‑Wiedemann syndrome, including surveillance, hypoglycemia treatment, tumor screening, cardiac evaluation, surgical interventions, and genetic counseling?

Management of Beckwith-Wiedemann Syndrome in Infants

Infants with Beckwith-Wiedemann syndrome require immediate implementation of tumor surveillance protocols with renal ultrasounds every 3 months from birth through age 7 years, combined with full abdominal ultrasounds and serum alpha-fetoprotein measurements every 3 months through age 4 years, alongside aggressive management of neonatal hypoglycemia. 1

Tumor Surveillance Protocol

The cornerstone of BWS management is structured cancer screening due to the 5-10% overall tumor risk, with Wilms tumor and hepatoblastoma being the most common malignancies.

Wilms Tumor Screening

• Renal ultrasound (including adrenal glands) every 3 months from birth through the 7th birthday 1
• This protocol applies regardless of molecular subtype in North American guidelines, though European centers may use risk-stratified approaches based on specific genetic/epigenetic alterations
• The screening extends to age 7 because while most tumors occur early, a measurable percentage develops up to age 8 years 1

Hepatoblastoma Screening

• Full abdominal ultrasound PLUS serum AFP every 3 months from birth through the 4th birthday 1
• After age 4, transition to renal-only ultrasounds every 3 months until age 7
• Most hepatoblastomas occur within the first year, with the oldest reported at 30 months 1
• AFP levels in BWS infants are naturally elevated compared to normal pediatric values—interpret trends over time, not isolated values 1
• AFP elevation often precedes ultrasound detection, enabling earlier intervention 1

Critical caveat: AFP interpretation requires expertise in BWS-specific reference ranges and should involve geneticists or pediatric oncologists familiar with these patterns 1.

Neonatal Hypoglycemia Management

Hypoglycemia from hyperinsulinism is a major acute concern requiring immediate intervention.

• Implement continuous glucose monitoring from birth 2
• Frequent feeding protocols
• Diazoxide or other hyperinsulinism-specific medications as needed
• Some infants require surgical intervention (partial pancreatectomy) for refractory cases
• Untreated hypoglycemia can cause permanent neurological damage, making this a mortality and quality-of-life priority

Macroglossia Management

Macroglossia causes feeding difficulties, airway compromise, and speech delays.

• Assess for airway obstruction immediately—this is a potential mortality issue in the neonatal period 2
• Tongue reduction surgery is indicated when macroglossia causes:
  • Feeding difficulties preventing adequate nutrition
  • Airway compromise
  • Speech impairment (typically assessed around 12-18 months) 3
• Surgery timing is individualized but often performed between 6-24 months

Abdominal Wall Defects

Omphalocele or umbilical hernia management follows standard surgical protocols:

• Immediate surgical consultation for omphalocele
• Staged repair may be necessary for large defects
• Umbilical hernias often managed conservatively initially, with surgical repair if persistent beyond age 4-5 years

Genetic Testing and Counseling

Molecular testing is mandatory for all suspected BWS cases to:

• Confirm diagnosis
• Determine recurrence risk (most cases are sporadic with low recurrence, but some molecular subtypes carry higher familial risk)
• Guide genetic counseling 1

The molecular subtypes include:

• IC2 loss of methylation (most common, ~2.6% tumor risk)
• IC1 gain of methylation (~28% tumor risk)
• Paternal uniparental disomy (~16% tumor risk)
• CDKN1C mutations (~6.7% tumor risk, includes neuroblastoma risk)

All recurrence risk determination and family testing must be performed by genetics professionals 1.

Multidisciplinary Follow-Up Structure

• Physical examination by genetics or pediatric oncology specialist every 6 months 1
• Growth monitoring using BWS-specific growth charts
• Developmental surveillance for cognitive and behavioral issues
• Orthopedic evaluation for limb-length discrepancy if hemihyperplasia present
• Cardiac evaluation if indicated by clinical findings (arrhythmias can occur) 3

Common Pitfalls to Avoid

1. Delaying tumor surveillance: Start immediately at diagnosis, not at first follow-up visit
2. Using standard pediatric AFP reference ranges: BWS infants have elevated baseline AFP—use BWS-specific values 1
3. Stopping surveillance too early: Continue renal ultrasounds through age 7, not just through toddlerhood
4. Inadequate hypoglycemia monitoring: Single normal glucose checks are insufficient—continuous or very frequent monitoring is required in the neonatal period
5. Missing somatic mosaicism: If blood testing is negative but clinical suspicion is high, test alternative tissues 4
6. Failing to refer to cancer predisposition specialists: These patients require subspecialty expertise for optimal outcomes 1

Divergent Evidence Note

While North American guidelines recommend uniform surveillance regardless of molecular subtype 1, European centers increasingly use risk-stratified protocols based on specific genetic/epigenetic alterations 1. The North American approach prioritizes broad screening given the 5-10% overall tumor risk and the significant mortality reduction with early detection, accepting higher false-positive rates to avoid missing any malignancies in this high-risk population.